3-isobutylsulphinyl-1,2,4-triazole | 71704-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-isobutylsulphinyl-1,2,4-triazole
• 英文别名: 5-(2-methylpropylsulfinyl)-1H-1,2,4-triazole
• CAS: 71704-42-2
• 化学式: C₆H₁₁N₃OS
• 分子量: 173.239
• InChiKey: PVUUCSULZQUAKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  77.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Azole derivatives as apelin receptor agonist
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10626096B2

  公开（公告）日：2020-04-21

  The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH═ or —CH═, X2 represents —CH═ or —N═, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

  本发明涉及一种作为芹菜素受体激动剂的新型唑衍生物以及用其治疗心血管疾病、糖尿病疾病、肾脏疾病、高血压和动脉硬化等的方法。本发明提供了由式（I）代表的化合物或其药理上可接受的盐 其中 X1 代表-NH═或-CH═，X2 代表-CH═或-N═，R1 和 R2 各自代表 C1 至 C6 烷氧基或类似物、R3 代表杂芳基（杂芳基可选择被甲基或类似基团取代）或类似基团，R4 代表 C1 至 C6 烷硫基或 C2 至 C6 烯基（C1 至 C6 烷硫基和 C2 至 C6 烯基各自可选择被一个羧基或类似基团取代）或类似基团。
• NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US20200347022A1

  公开（公告）日：2020-11-05

  The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X represents —N═ or —CH═, X 2 represents —CH═ or —N═, R 1 and R 2 each represent a C 1 to C 6 alkoxy group or the like, R 3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R 4 represents a C 1 to C 6 alkylthio group or a C 2 to C 6 alkenyl group (the C 1 to C 6 alkylthio group and the C 2 to C 6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.